Antwerp

• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C … Ended
  2024-514532-24-00 3 2022-06-23 Solid cancer tumors
• Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended
  2024-514570-43-00 5 2022-01-24 Renal cell carcinoma
• A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu … Ended
  2023-507189-17-00 4 2022-01-09 Muscle-Invasive Urothelial Carcinoma of the Bladder
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma
• A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Interm … Ended
  2024-516296-32-00 3 2021-11-11 Myelodysplastic Syndromes (MDS)
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 5 2021-09-17 Second- or Third-Line Recurrent or Metastatic Cervical Cancer
• An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn's disease previously included in the loss … Ended
  2024-514326-23-00 11 2021-09-10 Crohn's disease
• A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan … Ended
  2024-512227-36-00 9 2021-07-28 Advanced solid tumors
• An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Ad … Ended
  2023-506285-31-00 1 2021-04-21 Locally Advanced or Metastatic Solid Tumors
• Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) Ended
  2024-511140-37-00 4 2021-02-12 OligoRecurrent prostate cancer
• A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inop … Ended
  2024-512331-72-00 5 2020-12-22 Squamous Carcinoma of the Anal Canal
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• The Late Presenter Treatment Optimisation Study (LAPTOP) Ended
  2023-505167-36-00 5 2019-08-05 Patients who present late on during their acquisition of the HIV-1 (Hu
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in … Ended
  2024-512158-12-00 5 2018-12-14 Bladder Cancer Muscle-Invasive Bladder Cancer
• A Study to Evaluate Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally … Ended
  2023-504224-26-00 1 2018-07-03 Advanced tumors
• Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. Ended
  2024-511050-44-00 4 2018-05-16 Precursor B-acute lymphoblastic leukemia
• RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol … Ended
  2023-510189-28-00 6 2018-05-15 Rheumatoid Arthritis
• The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Ended
  2024-518736-37-00 6 2018-01-12 Risk of stroke by Atrial Fibrillation
• A clinical study to compare the safety, effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) o … Ended
  2023-507143-11-00 5 2017-11-08 Precancerous form of blood cancer in the bone marrow
• A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who … Ended
  2023-510557-42-00 4 2017-07-10 chronic lymphocytic leukemia
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma

Showing 217–240 of 245 trials